<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Sialyl Lewisx-i (SLX) was found in more than 40% of patients with <z:hpo ids='HP_0002488'>acute leukemia</z:hpo> or <z:hpo ids='HP_0005506'>chronic myelogenous leukemia</z:hpo>, and in about 20% of those with <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> or malignant <z:hpo ids='HP_0002665'>lymphoma</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>This <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> marker was absent in <z:hpo ids='HP_0000001'>all</z:hpo> patients with <z:hpo ids='HP_0001901'>polycythemia</z:hpo> vera, <z:e sem="disease" ids="C0040028" disease_type="Disease or Syndrome" abbrv="">essential thrombocythemia</z:e>, primary <z:hpo ids='HP_0011974'>myelofibrosis</z:hpo>, <z:hpo ids='HP_0005550'>chronic lymphatic leukemia</z:hpo>, <z:hpo ids='HP_0006775'>multiple myeloma</z:hpo>, and those with <z:hpo ids='HP_0002488'>acute leukemia</z:hpo> or malignant <z:hpo ids='HP_0002665'>lymphoma</z:hpo> in remission </plain></SENT>
<SENT sid="2" pm="."><plain>The marker was found in 8% and of the patients with <z:hpo ids='HP_0001973'>idiopathic thrombocytopenic purpura</z:hpo> and 33% of those with <z:hpo ids='HP_0001890'>autoimmune hemolytic anemia</z:hpo> but in no patient with <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> or <z:hpo ids='HP_0001889'>megaloblastic anemia</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>Immunostaining with SLX antibody showed that <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> cells of the patients with high levels of serum SLX were producing the SLX antigen </plain></SENT>
<SENT sid="4" pm="."><plain>The detection of this marker in the serum is thought to be useful not only in the diagnosis but also in the observation of the recurrence of the diseases </plain></SENT>
</text></document>